Please check your internet connection and try again.
```markdown
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **Pathological hypersecretory conditions:** 40 mg orally or intravenously twice daily, may be increased to a maximum of 80 mg intravenously or orally twice daily.
## Pediatric Dosing
* **Erosive esophagitis (ages 5 to 16 years):** 20 mg or 40 mg orally once daily, depending on weight.
* Weight < 40 kg: 20 mg once daily.
* Weight >= 40 kg: 40 mg once daily.
* Duration of treatment is typically up to 8 weeks.
## Dose Adjustments
* **Hepatic impairment:** Maximum daily dose of 40 mg orally. No dose adjustment necessary for IV.
* **Renal impairment:** No dose adjustment recommended.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, vomiting, dizziness, arthralgia.
* **Serious:** Clostridium difficile-associated diarrhea, bone fracture (hip, wrist, spine), hypomagnesemia (can be severe), vitamin B12 deficiency, systemic lupus erythematosus.
## Key Drug Interactions
* **Drugs requiring gastric pH for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, mycophenolate mofetil, dasatinib. Separate administration or monitor for reduced efficacy.
* **Methotrexate:** PPIs may increase methotrexate levels. Consider holding pantoprazole during methotrexate treatment.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Monitor for increased levels of drugs like clopidogrel and warfarin, though clinical significance can vary.
## Monitoring
* Monitor for signs and symptoms of *Clostridium difficile* infection.
* Consider periodic serum magnesium levels, especially with prolonged use (>3 months) or concurrent diuretic use.
* Monitor bone mineral density in patients at risk for osteoporosis.
* Monitor for symptoms of vitamin B12 deficiency with long-term use.
## Clinical Pearls
* Pantoprazole is generally less likely to interact with clopidogrel compared to omeprazole or esomeprazole due to weaker CYP2C19 inhibition.
* Administer oral pantoprazole 30-60 minutes before a meal.
* IV administration may be preferred in patients unable to take oral medications or with severe symptoms.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for complete and up-to-date details before making treatment decisions.
```
